当前位置: 范文大全  >  学生范文  >  研究生开题报告范文  >  内科研究生开题报告范文

内科研究生开题报告范文

  [2]. Volgman AS, Carberry PA, Stambler B, et al. Conversion efficacy and safety of intravenous ibutilide pared with intravenous procainamide in patientswith atrial flutter or fibrillation. J Am Coll Cardiol. 1998,31(6): 1414-9.

  [3]. Hongo  RH,  Themistoclakis  S,  Raviele  A,  et  a1.Use  of  ibutilide  in cardioversion of patients with atrial fibrillation or atrial flutter treated withclass IC agents. J Am Coll Cardiol. 2004,44(4): 864-8.

  [4]. Cheng J, Glatter K, Yang Y, et al. Electrophysiological response of the right atrium to ibutilide during typical atrial flutter. Circulation. 2002,106(7):814-9

  [5]. Baskin EP, Lynch ** Jr. Differential atrial versus ventricular activities of class III potassium channel blockers. J Pharmacol Exp Ther. 1998,285(1): 135-42.

  [6]. Buchanan  LV,  Kabell q Turcotte  UM,  et  al.  Effects      of ibutilide  on spontaneous  myocardial and  induced  ventricular  arrhythmias  in     24-hour  canine

  infarction: a parative study with sotalol and encainide. JCardiovasc Pharmacol. 1992,19(2): 256-63.

  [7]. Wesley RC Jr, Farkhani F, Morgan D,et al. Ibutilide: enhanced defibrillation via plateau sodium current activation. Am J Physiol. 1993,264(4 Pt 2):H 1269-74.

  [8]. Wood MA, Stambler BS, Ellenbogen KA, et al. Suppression of inducible ventricular tachycardia by ibutilide in patients with coronary artery disease. Ibutilide Investigators. Am Heart J. 1998,135(6 Pt 1): 1048-54.

  [9]. Levy S, Breithardt q Campbell RW, et al. Atrial fibrillation:  current knowledge  and  remendations  for  management.  Working  Group  on Arrhythmias of the European Society of Cardiology. Eur Heart J. 1998,19(9):1294-320

  [10]. Ricard P, Levy S, Trigano J, et al. Prospective assessment of the minimum energy needed for external electrical cardioversion of atrial fibrillation.  Am J Cardiol. 1997, 79(6): 815-6.

  [11].Reiffel JA. Intravenous Amiodarone in the Management of Atrial Fibrillation. J Cardiovasc Pharmacol Ther. 1999, 4(4): 199-204.

  [12]. Murray KT.  Ibutilide. Circulation. 1998, 97(5): 493-7.

  [13]. Ellenbogen KA, Clemo HF, Stambler BS, et al. Efficacy of ibutilide for termination of atrial fibrillation and flutter. Am J Cardiol. 1996, 78(8A): 42-5.

  [14].Yang  T,  Snyders  DJ,  Roden  DM.  Ibutilide,  a  methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K+  current  (IKr)  in  AT 1  cells.  Concentration-,  time-,  voltage-,  and use-dependent effects. Circulation. 1995, 91(6): 1799-806.

  [15]. Kowey PR, VanderLugt JT, Luderer JR. Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter. Am J Cardiol. 1996,78(8A): 46-52.

  [16]. Rodriguez I, Kilborn MJ, Liu XK, et al. Drug-induced QT prolongation in women during the menstrual cycle. JAMA. 2001,285(10): 1322-6.

  [17]. Wijffels MC, Kirchhof CJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation.A study in awake chronically instrumented goats .Circulation 1995,92(7): 1954-681

4、论文提纲

1.1对象与实验方法

  1.2结果

  1.3讨论

  2

  2.1对象与实验方法

  2.2结果

  2.3讨论

 

5、论文的理论依据、研究方法、研究内容

5.1、伊布利特对心脏电生理的影响实验方法。所有入选患者术前禁食,停用各种抗心律失常药物至少5个半衰期。在顺利完成左侧游离壁旁道射频消融术30min后,在X线透视引导下将四极电极导管分别置于高位右心房(HRA)、希氏束(HB)和右室心尖部(RVA) o静注伊布利特lmg(体重>_60kg都或0.01 mg/kg(体重<60kg者),均以5%葡萄糖50m1稀释后缓慢注射,给药时间l Omin.分别测量用药前、用药后即刻、用药后15min, 30min等不同时段各项心脏电生理参数,并描记12导联心电图至药后4h.采用HRASISI起搏法测量窦房结恢复时间((SNRT); HRA S 1 S2程序起搏法测量心房有效不应期(AERP)和房室结前传有效不应期(**N一ERP); RVA S1S2程序起搏法测量心室有效不应期(V ERP) ; HRA S 1 S 1起搏周长为600, 550, 500 ms;  HRA/ RV S1S2起搏起始周长为500/450ms ;

  5.2、静脉伊布利特与普罗帕酮转复心房厅卜动的临床随机对照观察用药方法。符合标准者按就诊或入院顺序随机分为伊布利特(北京红惠药厂,1 mgl支;批号030408)和普罗帕酮(广州明兴制药厂,35 mg/支;批号MC2501)两组,进行病史、体检及心电图、超声心动图、胸片检查和实验室检查(血常规和血生化检查,抗凝治疗患者查INR,育龄妇女查尿妊娠试验)。建立静脉通道,伊布利特组体重)60kg者首剂lm留次,如无效l 0min后可重复1 mg/次,体重<60kg者首剂0.01 mg/kg,如无效1 0min后可重复0.01 mg/kg;普罗帕酮组首剂70 mg/次,如无效10min后可再次予以35 mg,均以5%葡萄糖50mI稀释缓慢静脉注射,每次给药时间为1 0min,药后4小时内禁用延长QT间期的药物,包括m类抗心律失常药物、某些抗组胺药(H1受体阻滞剂)、三环或四环类抗抑郁药物。